Skip to main content
Fig. 5 | Journal of Neurodevelopmental Disorders

Fig. 5

From: Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety

Fig. 5

pERK1/2+ cell counts. Following the adult behavior battery (chronic treatment with saline (SAL) or 122.2 mg/kg CaCl2 in SAL (_Controls; equivalent amount of Ca2+ ions as in the 300 mg/kg acamprosate treated group) or 300 mg/kg acamprosate in saline (+Acamp)), mice were sacrificed and brain sections were stained for pERK1/2 (green) and NeuN (red). As with the behavior measures, there were no differences in pERK1/2+ cell counts between the SAL- and CaCl2-treated mice and therefore data are presented as combined control groups (controls). In the dentate gyrus (a, d–f), there was a significant effect of drug with pairwise comparison testing demonstrating a trend towards an increase in pERK1/2 positive cells in the KO_Controls group (KO + SAL pictured in e) compared to the untreated WT group (WT + SAL pictured in d). Additionally, the KO + Acamp group (f) had significantly fewer pERK1/2+ cells than the KO + Controls. In the DG, all pERK1/2+ cells were also NeuN+. There were no differences in PERK1/2+ cell counts observed in the auditory cortex (b) or in the visual cortex (c). Data shown are LS mean ± SEM; *p < 0.05; †p < 0.1; N.S. = not significant. n = 5–6 sections/group. Scalebar = 250 μm

Back to article page